Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522441 · ClinicalTrials.gov registry record · Phase 3
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Akorn.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,125
- Enrollment target
NCT03522441: Completed Phase 3 study, sponsored by Akorn.
NCT03522441 is a Phase 3 study that has completed, run by Akorn. The registered enrollment target is 1,125 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03522441, a Phase 3 study, has completed, sponsored by Akorn.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,125 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel (Greenstone LLC) in the treatment of acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Clindamycin 1% Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,125 participants |
| Start Date | 2018-04-27 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 3 |
What the finished NCT03522441 record still lists
NCT03522441 is an interventional study that assigns participants to a tested intervention. Its 1,125 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03522441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03522441 about?
NCT03522441 is a clinical study titled "Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris". This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel (Greenstone LLC) in the treatment of acne vulgaris.
What is the current status of trial NCT03522441?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,125 participants. The study started on 2018-04-27. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT03522441?
The interventions under investigation include: Placebo (DRUG), Clindamycin 1% Gel (DRUG).
Who is sponsoring clinical trial NCT03522441?
This trial is sponsored by Akorn, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03522441's enrollment target sits among peer trials
1,125 248th of 2000 higher than 1,753 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04421768 · 1,125 participants · NA
Effects of Systematic Cervical Exam Training on Labor and Delivery Care
- NCT06895148 · 1,125 participants · NA
ADHERE-LPV Advancing Delivery of High-Quality Evidence-Based Respiratory Efforts in Lung-Protective Ventilation
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
- NCT05438329 · 1,123 participants · Phase 1
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI